APPLICATION
ANDA091613
TYPE
ANDA
ORIGINAL APPROVAL
2012-12-26
LATEST ACTION
2021-02-11
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
NAFCILLIN SODIUMPrescription
NAFCILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
NAFCILLIN SODIUMPrescription
NAFCILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
Approval history
2021-02-11Labeling · Supplement 6 · standardAP
2021-02-11Labeling · Supplement 3 · standardAP
2018-07-11Manufacturing (CMC) · Supplement 4 · unknownAP
2012-12-26OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.